Compare · BTCY vs SYK
BTCY vs SYK
Side-by-side comparison of Biotricity Inc. (BTCY) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTCY and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 786.4x BTCY ($143.0M).
- SYK has been more active in the news (7 items in the past 4 weeks vs 2 for BTCY).
- SYK has more recent analyst coverage (25 ratings vs 3 for BTCY).
- Company
- Biotricity Inc.
- Stryker Corporation
- Price
- $0.48-25.30%
- $294.69+0.46%
- Market cap
- $143.0M
- $112.48B
- 1M return
- -
- +5.16%
- 1Y return
- -
- -22.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 7
- Recent ratings
- 3
- 25
Biotricity Inc.
Biotricity, Inc., medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated electrocardiogram (ECG) device and software solution. The company is based in Redwood City, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest BTCY
- SEC Form RW filed by Biotricity Inc.
- Biotricity Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 10-Q filed by Biotricity Inc.
- SEC Form NT 10-Q filed by Biotricity Inc.
- SEC Form 10-K filed by Biotricity Inc.
- SEC Form NT 10-K filed by Biotricity Inc.
- SEC Form PRE 14C filed by Biotricity Inc.
- Biotricity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Biotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Biotricity Inc.
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)